Target intelligence / Profile preview

GRID1 antisense RNA 1 (GRID1-AS1)

Target
GRID1-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA
01

Overview

GRID1 antisense RNA 1 (GRID1-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the GRID1 gene, which encodes a neuronal glutamate receptor subunit. GRID1-AS1 can regulate the expression of GRID1 and potentially other genes, typically by mechanisms involving transcriptional interference or RNA-RNA interactions. Antisense lncRNAs are known to participate in processes such as modulating mRNA abundance, chromatin structure, and epigenetic regulation. Although not a classical drug target, GRID1-AS1 may play roles in brain function and disease by influencing GRID1 gene expression and other pathways[3][6][8]. GRID1 antisense RNA 1 is specifically annotated as a long noncoding RNA, with mechanistic functions inferred from the general biology of antisense RNAs, including gene regulation, epigenetic modulation, and control of cellular phenotype[4][5][8]. Evidence for direct association with disease or drug development is currently lacking.

Other names
GRID1 antisense RNA 1 (non-protein coding)GRID1-AS1
02

Mechanism of action

No known drugs; general mechanism for antisense RNA-based approaches involve antisense oligonucleotides silencing target RNAs, gene activation or repression, or modification of chromatin and transcriptional machinery.

03

Biological functions

Regulation of gene expression (especially by modulating GRID1 expression)Transcriptional interference (potentially affecting nearby gene expression)Possible involvement in mRNA stability, chromatin organization, or epigenetic modulation (general functions of antisense RNAs)
04

Disease associations

Possible association with neurological disorders (via regulation of GRID1, which is linked to disorders like Rett syndrome and Spinocerebellar Ataxia 18)Potential involvement in immune regulation and other diseases, as lncRNAs are increasingly linked to various disorders
05

Safety considerations

No established safety concerns for therapeutics targeting GRID1-AS1; general antisense RNA therapies may have off-target and immune-related risks.

Beyond the preview

Go deeper on GRID1 antisense RNA 1 (GRID1-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRID1 antisense RNA 1 (GRID1-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call